Fruehauf JP - Search Results

1

Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer.

Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioglu O, Mechetner E, Kyshtoobayeva A, Chen SC, Hsueh S, McLaren CE, Wan YL. Su MY, et al. Among authors: fruehauf jp. J Magn Reson Imaging. 2003 Oct;18(4):467-77. doi: 10.1002/jmri.10380. J Magn Reson Imaging. 2003. PMID: 14508784

2

Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.

Su MY, Yu H, Chiou JY, Wang J, Nalcioglu O, Fruehauf JP, Mehta RS, Baick CH. Su MY, et al. Among authors: fruehauf jp. Technol Cancer Res Treat. 2002 Dec;1(6):479-88. doi: 10.1177/153303460200100608. Technol Cancer Res Treat. 2002. PMID: 12625775 Free article.

3

Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma.

Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP. Grant SW, et al. Among authors: fruehauf jp. Cancer Detect Prev. 1998;22(3):185-94. doi: 10.1046/j.1525-1500.1998.0oa18.x. Cancer Detect Prev. 1998. PMID: 9618039

4

Independent association of angiogenesis index with outcome in prostate cancer.

Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, McLaren CE, Li KT, Fruehauf JP. Mehta R, et al. Among authors: fruehauf jp. Clin Cancer Res. 2001 Jan;7(1):81-8. Clin Cancer Res. 2001. PMID: 11205922

5

Biomarker conservation in primary and metastatic epithelial ovarian cancer.

Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ, Fruehauf JP. Tewari KS, et al. Among authors: fruehauf jp. Gynecol Oncol. 2000 Aug;78(2):130-6. doi: 10.1006/gyno.2000.5837. Gynecol Oncol. 2000. PMID: 10926791 Free article.

6

Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.

Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP. Mechetner E, et al. Among authors: fruehauf jp. Clin Cancer Res. 1998 Feb;4(2):389-98. Clin Cancer Res. 1998. PMID: 9516927

7

In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.

Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP. Cloven NG, et al. Among authors: fruehauf jp. Gynecol Oncol. 2004 Jan;92(1):160-6. doi: 10.1016/j.ygyno.2003.09.030. Gynecol Oncol. 2004. PMID: 14751152

8

Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.

Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ, Fruehauf JP. Tewari KS, et al. Among authors: fruehauf jp. Gynecol Oncol. 2005 Sep;98(3):360-8. doi: 10.1016/j.ygyno.2005.04.036. Gynecol Oncol. 2005. PMID: 16000215 Free article.

9

Breast cancer survival and in vitro tumor response in the extreme drug resistance assay.

Mehta RS, Bornstein R, Yu IR, Parker RJ, McLaren CE, Nguyen KP, Li KT, Fruehauf JP. Mehta RS, et al. Among authors: fruehauf jp. Breast Cancer Res Treat. 2001 Apr;66(3):225-37. doi: 10.1023/a:1010604502627. Breast Cancer Res Treat. 2001. PMID: 11510694

10

Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival.

Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nicosia SV, Yeatman TJ. Coppola D, et al. Among authors: fruehauf jp. Am J Clin Pathol. 1998 Jul;110(1):16-23. doi: 10.1093/ajcp/110.1.16. Am J Clin Pathol. 1998. PMID: 9661918

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters